These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 37511609)

  • 21. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
    Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
    J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different
    Ye ZH; Long H; Zhao ZR
    J Immunol Res; 2022; 2022():8513747. PubMed ID: 35528615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
    Jafarnejad M; Gong C; Gabrielson E; Bartelink IH; Vicini P; Wang B; Narwal R; Roskos L; Popel AS
    AAPS J; 2019 Jun; 21(5):79. PubMed ID: 31236847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
    Isaacs J; Stinchcombe TE
    Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer.
    Kerrigan K; Puri S
    Curr Oncol Rep; 2022 Jan; 24(1):113-123. PubMed ID: 35060001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
    Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Alonso-Viteri S; Khosravi-Shahi P
    Clin Lung Cancer; 2021 Sep; 22(5):381-389. PubMed ID: 33875382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
    Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
    Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer.
    Tsoukalas N; Kiakou M; Tsapakidis K; Tolia M; Aravantinou-Fatorou E; Baxevanos P; Kyrgias G; Theocharis S
    J BUON; 2019; 24(3):883-888. PubMed ID: 31424637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
    Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer].
    Guo C; Zhang J; Li S
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):524-533. PubMed ID: 35899452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest.
    Kim L; Coman M; Pusztai L; Park TS
    Ann Surg Oncol; 2023 Oct; 30(11):6441-6449. PubMed ID: 37349612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.